Objectives: This study aims to compare different modalities used in the treatment of deep vein thrombosis (DVT) and to identify risk factors for post-thrombotic syndrome (PTS).
Deep vein thrombosis (DVT) is a disease with 0.05% incidence. [1] Immobility, trauma, elderly age, surgical operation, and malignancy are predisposing factors for DVT. Deep vein thrombosis is an important cause of mortality and morbidity associated with pulmonary embolism (PE) and post-thrombotic syndrome (PTS). Anticoagulation is the mainstay of DVT treatment. Most patients with DVT can be treated in the outpatient setting with low-molecularweight heparin (LMWH) and vitamin K antagonist (VKA) or direct-acting oral anticoagulants (DOACs). Catheter-directed thrombolysis (CDT) is an alternative option for the treatment DVT and is known to decrease the incidence of PTS. Patients who are most likely to benefit from CDT have iliofemoral DVT, symptoms for <14 days, good functional status, a life expectancy of >1 year, and a low risk for bleeding. [2] The acute venous thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial was designed to test whether interventional treatments had advantages over medical treatment. [3] In this study, the follow-up results of patients undergoing interventional and medical treatment options at 24 months were analyzed.
All patients with iliofemoral and femoropopliteal thrombosis were included in the study, and no significant difference was found in terms of the development of PTS and recurrent DVT. The patients with iliofemoral involvement had lower rates of PTS (25%) and bleeding rates were found to be lower and no mortality was observed. [3] Our mid-term results based on ultrasoundaccelerated CDT experiences have been previously published. [4] In the present study, we aimed to compare medical and interventional modalities used in the treatment of DVT and to identify risk factors for PTS.
PATIENTS AND METHODS
This retrospective study included a total of 217 patients (119 males, 98 females; mean age 51.2±18.1 years; range, 15 to 96 years) with DVT who received medical and interventional methods between August 2012 and September 2018. Data were obtained from the hospital records and telephone calls. The final functional status and clinical presentation of the patients were obtained through telephone interviews with outpatient examination records. In all patients, malignancy, immobility, traumas, history of orthopedic surgery, other major surgical interventions, previous vascular surgery, pregnancy and contraception, coagulopathies, long journey, oral contraceptive use, advanced age, obesity, rheumatologic diseases, working conditions were questioned. Deep vein thrombosis was considered provoked in the presence of a risk factor, while it was considered non-provoked, if no risk factor was present. The patients who had >5 points of Villalta scores, 8 points of Venous Clinical Severity Score (VCSS) or who had venous ulcer were accepted as having PTS.
In the presence of positive medical history for PE, the patients were considered to have PE. The predisposing factor was accepted to be present within two months before the development of DVT in trauma cases. Malignancies were not considered as a predisposing factor, if the cure was six months or longer. Pregnancy and postpartum (the first two months after delivery) periods were considered predisposing factors for DVT. We classified the levels of involvement in relation to the first ultrasound imaging according to the Lower Extremity Thrombosis (LET) Classification. [5] The patients were divided into two groups: the interventional group (Group I, n=35) receiving interventional methods such as surgical, mechanical, or pharmacomechanical thrombectomy and the medical group (Group M, n=182) receiving medical treatment alone. A written informed consent was obtained from each patient. The study protocol was approved by the Ethics Committee of Clinical Researches of Health Sciences University, Faculty of Medicine, Bağcılar Training and Research Hospital (Protocol No: 2018.08.2.03.080). The study was conducted in accordance with the principles of the Declaration of Helsinki.
Medical treatment
The routine choices of anticoagulation are VKA, LMWH, and DOACs for medical treatment of DVT in our clinic. The LMWH treatment was preferred in the patients with a history of malignancy and high risk for bleeding. In the patients with poor compliance to control visits and bloodwork including the international normalized ratio (INR) control, DOACs were preferred. The patients on warfarin treatment were called to the INR check, until they reached the therapeutic value. The control INR value was increased to 2 to 2.5, and the followup intervals were extended (two weeks) with monthly INR monitoring.
In most patients, DVT treatment was terminated after three to six months, unless there was a risk for recurrence and a control venous Doppler ultrasonography (US) was performed. Extended treatment (>12 months) was performed in the patient group with high risk factors with recurrence and PE. Twenty-four of Group I patients (68.6%) and 83 of Group M (50%) patients received extended treatment (p=0.043).
Interventional treatment
Interventional treatment was applied to the selected iliofemoral DVT patients who were diagnosed in the acute period. Interventional methods were preferred primarily in the patients who did not have any contraindications for thrombolytics, no restrictions for ambulation, young, and had a significant increase in diameter and tension affected the extremity.
We used CDT, ultrasound-accelerated thrombolytic therapy, and rheolytic thrombectomy (RT). All the interventional treatment methods we performed in our clinic were performed under scopy. All patients were given prone position, and they were monitored by electrocardiography, blood pressure (with cuff), and oxygen saturation (SpO 2 ). In the prone position, both popliteal regions of the patient were cleaned with an antiseptic solution and covered sterile. Under local anesthesia, a 6F or 8F sheath was placed to the ipsilateral popliteal vein under the guidance of US. A total of 5,000 IU unfractionated heparin was administered to all patients at the beginning of the procedure. In case of stenting, the sheath was replaced with larger sizes (10F).
Catheter-directed thrombolysis therapy was given via a multi-side hole catheter in the thrombotic segment thereby providing a thrombolytic agent (Alteplase-Actilyse 50 mg/50 mL vial, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany) locally into the thrombus. Alteplase infusion was administered at a dose of 0.05 mg/kg/h. Fibrinogen levels were monitored at four-h intervals during the infusion. The treatment was continued at the same dose, when the fibrinogen level was >150 mg/dL. If fibrinogen measurements fell between the range of 100 to 150 mg/dL, alteplase was reduced to half-dose. When the fibrinogen was below 100 mg/dL, the infusion was discontinued and infusion therapy was terminated, if the following two measurements were below 100 mg/dL.
Ultrasound-accelerated CDT (EKOS Corporation
Bothell, WA, USA) includes a drug application lumen, temperature sensor, and cooling system. Under the scopy, 2.2-MHz energy was applied from this catheter inserted into the lumen through the ipsilateral popliteal vein. The effect of fibrinolytic agent on thrombus was increased by providing prolongation and relaxation of the fibrin fibers through radial ultrasonic waves. The results of our experience with this method have been published previously. [4] Rheolytic thrombectomy, power pulse spray, and rapid lyse (AngioJet Boston Scientific, Ballybrit Business Park. Galway, Ireland) aims to manage the mechanical and medical thrombectomy therapies simultaneously. The catheter has a combination of a serum-spraying mechanism and a local vacuum providing mechanism of about 600 mmHg at a rate of about 160 m/s. In this way, the thrombus, which is mechanically fragmented by the serum jet, is removed by simultaneous aspiration. During the procedure, the effectiveness of the process is increased with the use of a local thrombolytic agent. In the patients with power pulse, 10 mg of alteplase was placed in 500 mL serum and applied through thrombus and waited almost 30 min. In the patients with a high thrombus burden, the patient was treated with alteplase (10 mg/500 mL) in the serum who would undergo RT (rapid lyse). In the case of fully occluded vessels, the recommendation of the manufacturer is based on a safe processing time of 600 sec. The patients with a good hydration and thrombus burden were treated for longer period (up to 770 sec). The patients who had a high burden of thrombus due to this restriction were treated with CDT for 24 h before RT. Using this method, which is a routine interventional treatment modality in our clinic, the need for thrombolytic infusion after treatment was reduced. If CDT was not used, the patients could be transferred to the ward or discharged after being monitored in the intensive care unit (ICU) on the day of the procedure. To prevent hemolysis-induced renal dysfunction, the patients were significantly hydrated and renal markers were followed during the hospital stay.
The patients who were scheduled for treatment were admitted to the ICU, and hydration was commenced along with antiplatelet and anticoagulant therapies. Heparin was used primarily during the hospital stay. The target activated partial thromboplastin time value was between 40 and 60 sec. Leg elevation was applied to all patients before and after the procedure. The duration of ICU follow-up was at least one day. The patients who underwent CDT for the treatment were kept in the ICU during infusion. In case of massive hematuria or decreased hematocrit during infusion, thrombolytic therapy was discontinued and necessary supportive therapies including transfusion were employed.
All patients were prescribed by appropriate anticoagulant and antiplatelet treatments at the time of discharge. Leg elevation and regular ambulation were also recommended to all patients.
Follow-up
The patients who were discharged were called to the first-and third-month follow-up visits and, then, to the six-month follow-up visit. All patients were informed about recommended lifestyle changes. Compression stockings were recommended to all patients and venotonic drugs were prescribed in case of significant symptoms.
Statistical analysis
Statistical analysis was performed using the SPSS for Windows version 15.0 software (SPSS Inc., Chicago, IL, USA). Descriptive data were expressed in mean±standard deviation (SD), median (min-max), or number and frequency. The Pearson chi-square test (or Fisher's exact test, where applicable) was used to compare discrete variables, while the independent t-test was used for continuous variables between the groups. Follow-up periods without recurrence and PE were calculated using the Kaplan-Meier method and curves were compared using a log-rank test. Recurrence during follow-up, development of PTS, and Villalta and VCSS scores were analyzed during follow-up. A p value of <0.05 was considered statistically significant. The distribution of patients with risk factors is shown in Table 1 . According to the developmental mechanisms, provoked DVT was observed in 11 patients (31.4%) in Group I and in 95 patients (52.2%) in Group M (p=0.023). According to the lateralization, in Group I, 77.1% (n=27) had left, 20.0% (n=7) had right, and 2.9% (n=1) had bilateral DVT. The lateralization rates of Group M were as follows: 58.8% (n=107) left, 39.0% (n=71) right, and 2.2% (n=4) bilateral DVT. Although the left leg involvement rate was higher in Group I, the difference was not statistically significant (p=0.083).
RESULTS
Demographic data of the patients are summarized in Table 2 . As expected, more patients in Group I had proximal DVT. Another striking feature is the higher percentage of provoked DVT in Group M which is statistically significant.
The procedures applied to the patients are shown in Table 3 . Thirty-one patients (88.6%) who underwent interventional procedures were treated in the acute period (within the first 14 days); three (8.6%) in the subacute period (between 14 and 28 days), and one (2.9%) in the chronic period (>28 days). The mean length of hospital stay in the ICU was 2.8±1.8 (range, 1 to 7) days, and the mean duration of hospitalization was 7.6±5.1 (range, 2 to 28) days. No mortality was observed in Group I perioperatively and during the first planned anticoagulation treatment.
The follow-up data of the patients are summarized in Table 4 . There was no statistically significant The recurrence rate was 22.9% in Group I (n=8) and 16.9% in Group M (n=23), indicating no statistically significant difference (p=0.198). According to the Kaplan-Meier analysis, one-and two-year recurrence-free survival rates were 91.9±3.5% and 83.1±5.8% in Group M and 80.0±8.1% and 73.3±9.8% in Group I, respectively (p=0.093) (Figure 1 ). There were no patients with PE during and after the procedure. However, PE was seen in five patients (6.4%) during follow-up in Group M.
Mortality was seen in two patients (5.7%) in Group I and in six patients (13.9%) in Group M which were not related to DVT. According to Kaplan-Meier method, one-year and two-year survival rates were 96.7±3.3% in Group I and 94.4±2.3% in Group M, indicating no statistically significant difference between the groups (Figure 2 ).
Anticoagulant-associated bleeding rates were 27.6% (n=8) in Group I and 41.0% in Group M (n=32), indicating no statistically significant difference between the groups (p=0.195). When the anticoagulant therapies used in 107 patients with complete follow-up data, 17 patients (15.9%) received LMWH, 32 patients (29.9%) received warfarin, 50 patients (46.7%) received DOACs, seven patients (6.5%) were on aspirin, and one patient (0.9%) did not receive the recommended treatment.
Two patients had massive hematuria. The first of these patients (21 years old, male) was on CDT after RT, and thrombolytic infusion was discontinued due to hematuria. The other patient (86 years old, female) received ultrasound-accelerated thrombolytic therapy. Thrombolytic infusion was discontinued due to hematuria, and two units of erythrocyte suspension and one unit of fresh frozen plasma replacement were performed. The patient was followed for seven days in the ICU and 13 days in the hospital in total, and her complaint regressed with supportive care. Direct oral anticoagulants were used for post-discharge follow-up. She had retroperitoneal hemorrhage and she died from an unknown reason 27 months after the procedure.
One patient (2.9%) who was treated with RT without a thrombolytic agent and DOAC therapy had intraventricular bleeding two months after the procedure and died. Another patient who was lost-to-follow-up after the procedure was prescribed with warfarin, and no major complication was observed, except for mild ecchymosis, as reported by the patient during telephone interview. Eighteen months after the procedure, the patient was admitted to the emergency department with a complaint of worsened general condition. However, a detailed medical data was unable to be reached, as the patient died in an external center with an unknown reason.
Access site-related hematoma occurred in one patient (2.9%) in the popliteal region which was spontaneously regressed completely during follow-up.
In six patients (3.3%) in Group M, major bleeding (gastrointestinal bleeding n=5, uterus hematoma n=1) and minor bleeding in seven patients (ecchymosis, gingival bleeding, and increased menstruation bleeding) were observed. During follow-up, six patients (3.3%), all of whom were malignant, died. Two of these patients (1.1%) were those with major bleeding due to anticoagulant therapy (gastrointestinal bleeding).
Acute renal failure developed in one patient (2.9%) during the ICU stay. The patient received dialysis treatment three months after discharge, and his blood urea and creatinine levels returned to normal and he remained free from dialysis treatment for five months.
DISCUSSION
In the present study, interventional treatment and medical treatment for lower extremity DVT were compared. The main findings of our study included that a higher number of patients in Group I received extended treatment and the mean PTS rate calculated by the VCSS and Villalta scores were lower in these patients in the mid-term.
The Catheter-directed Venous Thrombolysis (CaVENT) and ATTRACT trials are two major studies in which interventional and medical treatment methods are compared in terms of PTS. The ATTRACT trial [3] resulted in the failure of interventional treatments to show the expected benefit in preventing PTS development, compared to medical therapy (PTS rates were 48% in pharmacomechanical thrombectomy group and 47% in control group). In our study, the severity of symptoms was significantly lower as evident with significantly lower Villalta and VCSS scores in Group I (Table 4 ). When the ATTRACT trial was compared with our study, we believe that the difference in PTS reports was related to the underestimation of the patients' symptoms. In our clinic, interventional treatment modalities were preferred in Class 3-4 patients according to the LET classification. We found that the success of the Group I was significantly higher than Group M. In the CaVENT trial, which first demonstrated the efficacy of thrombolytic therapy, the five-year results of 176 patients (n=87 CDT, n=89 controls) were evaluated. [6] The PTS development rates were 43% and 71% (p<0.0001) in the CDT group and in the control group, respectively.
In a study including 38 patients who underwent RT + CDT, the PTS development rate was reported as 17% during a 20-month follow-up period. [7] In another study, 68 patients who underwent RT with the AngioJet were evaluated retrospectively and the mean pre-and postoperative VCSS scores were found to be 13.1±2.2 and 4.0±1.3, respectively (p=0.01), while the mean Villalta scores decreased from 12.9±2.8 to 5.5±1.4 postoperatively (p<0.001). [8] Only three patients had minor bleeding. However, none of the patients had major complications such as major bleeding, PE, or death. Therefore, the results of our study are consistent with previous studies suggesting that PTS can be significantly reduced by the interventional treatment of DVT. The bleeding complications after CDT may be impractical; however, as previously been discussed, [3] even after the ATTRACT trial, the practice in DVT treatment remained unchanged for the physicians. The main advantage of the interventional treatment modality is that improved Villalta scores are prominent with low morbidity rates in selected cases.
In the Early Coronary Angiography Versus Delayed Coronary Angiography (PEARL) trial, 329 patients had a recurrence rate of 94%, 87%, and 83% at three, six, and 12 months during follow-up, respectively. [9] Major bleeding rate was 3.6% and none was associated with the AngioJet use. In our study, the mean rate of the patients without recurrence in Group I was 73.3±9.8 at four years; the mean survival without recurrence was 1.6±1.8 years; and the total bleeding rate was 25.7% (n=9). The proportion of the patients receiving prolonged treatment in the interventional treatment group was significantly higher. This high rate should be considered as another factor which reduces the recurrence rate.
In a study by Shen et al., [10] 79 patients who underwent RT (with power pulse spray) and 119 patients with CDT were examined for kidney injury. Acute renal injury was 22.8% in patients with RT+thrombolytic therapy (p=0.013). In our study, one patient who developed acute renal failure had dialysis treatment for three months and, then, renal functions returned to normal. Renal injury after RT is an important risk for surgeons to consider. The low rate of renal dysfunction in our study group can be explained by the liberal hydration protocol applied to the patients in our clinic.
In their study, Sharifi et al. [11] published the results of 133 patients treated with iliac and femoropopliteal venous stents. The reported stent thrombosis rate was 4%. There is also a study regarding the risk for intimal hyperplasia and DVT in the contralateral extremity after migration or extension of the stent to the inferior vena cava. [12] The stent patency rates of the patients with stent implantation by direct and progressive methods were found to be 93.5% and 97.8%, respectively (p=0.323) and the mean Villalta scores were found to be 4.2±2.5 and 2.1±1.9, respectively. [13] In addition, one-year patency rates were reported as higher than 90% with specialized vein stents. However, the patency rates for Wallstent® were previously reported as below 70%, particularly in PTS patients. [14] In the present study, we applied extended treatment (>12 months) to the patient group with high risk factors with recurrence and PE. In 24 patients (68.6%) of Group I and 83 patients (50%) of Group M received extended treatment (p=0.043). We believe that the prolonged treatment of most of the Group I patients has a share in preventing the development of PTS in this patient group.
Limitations of the study
The main limitations of the study are its retrospective nature and missing patient data. Patients' communication data were incomplete or inaccurate, patients did not attend to the follow-up regularly or follow-up visits in external centers. Therefore, the efficacy of the treatments which were applied was unable to be evaluated individually. Another limitation is the probability of incorrect entry of records in the hospital registry systems. We believe that many patients were unable to be drawn from the hospital records due to miscoding or other problems with the electronic record systems. The patients with missing data (incomplete follow-up data could not be completed) were excluded from the analysis in terms of recurrence and development of PTS. However, the rate of PTS development in Group M was found to be close to the ATTRACT trial. In Group I, low rates were found. Although we acknowledge that these low rates are due to lack of data, it should be also considered that there was a significant difference between the patients.
In conclusion, the PTS development rate decreased significantly over two years after interventional treatments. Symptoms were significantly lower as measured with the Villalta and VCSS scores. Based on these findings, necessary infrastructure should be developed to increase interventional treatment practices, and physicians should be able to apply these methods effectively with an increased learning curve through relevant training programs. Thus, a considerable progress can be made in terms of DVT treatment and prevention of complications.
